Nontuberculous Mycobacterial Infections Therapeutics Market Size in the 7MM is projected to grow at a significant CAGR by 2034, estimates DelveInsight

DelveInsight's "Nontuberculous Mycobacterial Infections Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of NTM Infections, historical and forecasted epidemiology, as well as the NTM Infections market trends in the United States.

Explore the intricate details of the Nontuberculous Mycobacterial Infections Market @ Nontuberculous Mycobacterial Infections Market Size- https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Key Takeaways from the Non-Tuberculous Mycobacterial Infections Market Report
• According to DelveInsight's epidemiology model, the total Nontuberculous Mycobacterial Infections diagnosed prevalence was approximately 108 thousand cases in the US in 2023 which are expected to increase during the forecast period (2024-2034) due to several factors. An aging population and rising rates of chronic lung diseases like COPD and bronchiectasis contribute significantly. Enhanced awareness and improved diagnostic tools have led to more frequent identification and reporting of these infections.
• In the US, Nontuberculous Mycobacterial Infections exhibit a female preponderance compared to males in 2023. Of the total Nontuberculous Mycobacterial Infections diagnosed prevalent cases, femaes accounted for nearly 68%, while males accounted for approximately 32%. The prevalence of NTM infections is higher in females due to a combination of biological, behavioral, and environmental factors. Females are more likely to have certain chronic lung diseases, such as bronchiectasis, which predispose them to NTM infections. Hormonal differences and immune system variations may also play a role.
• In 2023, among the species-specific cases, M. avium accounted for the highest Nontuberculous Mycobacterial Infections diagnosed prevalent cases in the US accounting for nearly 76 thousand cases followed by M. abscessus with nearly 14 thousand cases, and others (M. kansasii, M. xenopi, etc.) with approximately 18 thousand cases. The diagnosed prevalent cases of NTM infections caused by M. avium species are higher in the United States due to the widespread presence of M. avium in the environment, including soil, water, and household plumbing systems, which increases the likelihood of exposure.
• In the US, there were approximately 86 thousand Nontuberculous Mycobacterial Infections diagnosed prevalent cases among pulmonary type and nearly 22 thousand cases among extrapulmonary type in 2023.
• In the US, the highest number of Nontuberculous Mycobacterial Infections diagnosed cases were moderate followed by mild and severe cases with approximately 58 thousand, 36 thousand, and 13 thousand cases respectively in 2023.
• The leading Non- Tuberculous Mycobacterial Infections Companies such as Spero Therapeutics, Savara Pharmaceuticals, Mallinckrodt Inc., Paratek Pharmaceuticals Inc., Revimmune, and others
• Promising Non- Tuberculous Mycobacterial Infections Therapies such as SPR720, Molgramostim, Thiolanox (Nitric Oxide), NUZYRA (omadacycline), CYT 107, and others

Navigate the complexities of the Nontuberculous Mycobacterial Infections Market @ Nontuberculous Mycobacterial Infections Treatment Market- https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Non-Tuberculous Mycobacterial Infections Epidemiology Segmentation in the 7MM
• Total Prevalent Cases of NTM Infections in the US
• Total Diagnosed Prevalent Cases of NTM Infections in the US
• Gender-specific Cases of NTM Infections in the US
• Species-specific Cases of NTM Infection in the US
• Type-specific Cases of NTM Infections in the US
• Severity-specific Cases of NTM Infections in the US

Download the report to understand which factors are driving Non-Tuberculous Mycobacterial Infections epidemiology trends @ Non-Tuberculous Mycobacterial Infections Prevalence- https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Nontuberculous Mycobacterial Infections Marketed Drugs
• ARIKAYCE (amikacin liposome inhalation suspension): Insmed
ARIKAYCE is the first FDA-approved therapy indicated for the treatment of MAC lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. ARIKAYCE is a novel, inhaled, once-daily formulation of amikacin, an established antibiotic historically administered intravenously and associated with severe toxicity to hearing, balance, and kidney function. Insmed's proprietary PULMOVANCE liposomal technology enables the delivery of amikacin directly to the lungs, where lung macrophages take it up, targeting the site of infection. This approach prolongs the release of amikacin in the lungs while limiting systemic exposure. ARIKAYCE is administered once daily using the Lamira Nebulizer System manufactured by PARI Pharma GmbH.

Nontuberculous Mycobacterial Infections Emerging Drugs Profile
• Epetraborole: AN2 Therapeutics
Epetraborole (EBO), developed by AN2 Therapeutics, is a novel, once-daily, orally administered investigational treatment for patients with chronic NTM lung disease. Epetraborole is a boron-containing small molecule inhibitor of bacterial leucyl-tRNA synthetase, or LeuRS, an enzyme that catalyzes the attachment of leucine to transfer RNA, or tRNA, molecules, an essential step in protein synthesis. Epetraborole forms a complex with a tRNALEU molecule, trapping the terminal ribonucleotide of tRNALEU in the editing site of the enzyme, which prevents the synthetic site from attaching leucine to tRNALEU thus shutting down tRNA leucylation and leading to a block in protein synthesis. Currently, the drug is in Phase II/III of clinical development for the treatment of patients with NTM lung disease. AN2 Therapeutics intends to expand the indication targeted by epetraborole by pursuing development in other mycobacterial diseases, including treatment-naïve MAC lung disease. AN2 Therapeutics also intends to conduct trials in which they plan to incorporate epetraborole as part of first-line combination treatment for treatment-naive patients with NTM lung disease and M. abscessus lung infections.

• MNKD-101 (Clofazimine Inhalation Suspension): Mannkind Corporation
MNKD-101, a nebulized formulation of clofazimine, is being developed for the treatment of severe chronic and recurrent pulmonary infections, including NTM lung disease. An orally inhaled formulation of clofazimine is anticipated to offer several clinical advantages over the current solid oral dosage form of this drug. MNKD-101 has been designated as both an orphan drug and a qualified infectious disease product by the US FDA for the treatment of pulmonary NTM infections. Mannkind is also assessing the feasibility of developing a dry-powder formulation of clofazimine using Mannkind's technosphere formulation technology. MNKD-101 is designated with fast-track designation by the US FDA for the treatment of NTM lung infections. Mannkind intends to commence a Phase III registration study of MNKD-101 in the US in the second quarter of 2024.

• SPR720 (Fobrepodacin): Spero Therapeutics
SPR720, developed by Spero Therapeutics, is a broad-spectrum oral antibiotic designed to treat NTM pulmonary disease. SPR720 employs a novel mechanism and has no known cross-resistance with marketed antibiotics. SPR720 has demonstrated a broad spectrum of activity in preclinical studies against the most common organisms causing NTM infections, including M. avium complex, or MAC, M. kansasii, and M. abscessus. SPR720 is applicable to both nonrefractory and refractory patients.

Unlock insights into the Nontuberculous Mycobacterial Infections Market @ Nontuberculous Mycobacterial Infections Market Drivers and Barriers- https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Non- Tuberculous Mycobacterial Infections Therapies and Companies
• SPR720: Spero Therapeutics
• Molgramostim: Savara Pharmaceuticals
• Thiolanox (Nitric Oxide): Mallinckrodt Inc.
• NUZYRA (omadacycline): Paratek Pharmaceuticals Inc.
• CYT 107: Revimmune

Explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Nontuberculous Mycobacterial Infections Market Forecast @ https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Scope of the Non- Tuberculous Mycobacterial Infections Market Report
• Study Period: 2020-2034
• Coverage: 7MM
• Non-Tuberculous Mycobacterial Infections Companies: Spero Therapeutics, Savara Pharmaceuticals, Mallinckrodt Inc., Paratek Pharmaceuticals Inc., Revimmune, and others
• Non-Tuberculous Mycobacterial Infections Therapies: SPR720, Molgramostim, Thiolanox (Nitric Oxide), NUZYRA (omadacycline), CYT 107, and others
• Non-Tuberculous Mycobacterial Infections Therapeutic Assessment: Non- Tuberculous Mycobacterial Infections current marketed and Non- Tuberculous Mycobacterial Infections emerging therapies
• Non-Tuberculous Mycobacterial Infections Market Dynamics: Non- Tuberculous Mycobacterial Infections market drivers and Non- Tuberculous Mycobacterial Infections market barriers
• Non- Tuberculous Mycobacterial Infections Unmet Needs, KOL's views, Analyst's views, Non- Tuberculous Mycobacterial Infections Market Access and Reimbursement

Gain a strategic edge in the Nontuberculous Mycobacterial Infections Market @ Nontuberculous Mycobacterial Infections Clinical Trials Assessment- https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Table of Contents
1. Non- Tuberculous Mycobacterial Infections Market Report Introduction
2. Executive Summary for Non- Tuberculous Mycobacterial Infections
3. SWOT analysis of Non- Tuberculous Mycobacterial Infections
4. Non- Tuberculous Mycobacterial Infections Patient Share (%) Overview at a Glance
5. Non- Tuberculous Mycobacterial Infections Market Overview at a Glance
6. Non- Tuberculous Mycobacterial Infections Disease Background and Overview
7. Non- Tuberculous Mycobacterial Infections Epidemiology and Patient Population
8. Country-Specific Patient Population of Non- Tuberculous Mycobacterial Infections
9. Non- Tuberculous Mycobacterial Infections Current Treatment and Medical Practices
10. Non- Tuberculous Mycobacterial Infections Unmet Needs
11. Non- Tuberculous Mycobacterial Infections Emerging Therapies
12. Non- Tuberculous Mycobacterial Infections Market Outlook
13. Country-Wise Non- Tuberculous Mycobacterial Infections Market Analysis (2020-2034)
14. Non- Tuberculous Mycobacterial Infections Market Access and Reimbursement of Therapies
15. Non- Tuberculous Mycobacterial Infections Market Drivers
16. Non- Tuberculous Mycobacterial Infections Market Barriers
17. Non- Tuberculous Mycobacterial Infections Appendix
18. Non- Tuberculous Mycobacterial Infections Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432, Las Vegas, Nevada 89107, United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading healthcare business consultant and market research firm focused exclusively on life sciences. It supports pharmaceutical, dental, and diagnostics companies by providing comprehensive end-to-end solutions to improve performance. It also offers healthcare consulting services that help accelerate business growth through data-driven market insights and strategic decision-making.

This release was published on openPR.